In vitro diagnostics (IVD) companies reported a mix of overall growth, with many noting continuing challenges in their diagnostics divisions for recent quarterly financial results. Thermo Fisher Scientific, QuidelOrtho, and Danaher reported the strongest growth. About half of the global IVD companies reported decreased sales in diagnostics, largely due to China’s shift to volume-based procurement […]
Global IVD Woes in China Should Resonate with US Labs
Manufacturers’ quarterly earnings show a difficult Chinese market, but growth occurs elsewhere
- By Mark Terry
- > From the Volume XXXIII, No. 3 - March 2, 2026 Issue
- Tags: Abbott Laboratories, AMR, anti-microbial resistance, Association for Diagnostics and Laboratory Medicine conference, Atellica, BD, Beckman Coulter, Becton Dickinson and Company, Bernd Montag, Bio-Rad Laboratories, BioFire SpotFire, bioMerieux, biosciences, Blackstone, Brian Blaser, CDC, Centers for Disease Control and Prevention, Cepheid, China, Danaher, Exact Sciences, G2 Intelligence, Hologic, immunoassay, in vitro diagnostics, IVD, ivd/lab informatics, Jiangxi Provincial Health Security Administration, John Osiecki PhD, leica biosystems, Marc Casper, Matt Sause, microbiology, molecular biology, molecular diagnostics, Norman Schwartz, Parse Biosciences, point-of-care diagnostics, President Donald Trump, Qiagen, QuidelOrtho, Rainer Blair, rapid diagnostics, Robert Ford, roche diagnostics, Roche Group, Roop K. Lakkaraju, Siemens Healthineers, sysmex, the dark report, Thermo Fisher Scientific, Thierry Bernard, Thomas Pollen, TPG, US Supreme Court, VBP, volume-based procurement, Waters Corporation
